TRAF6 anticorps

N° du produit ABIN2666284

L’anticorps Souris Monoclonal anti-TRAF6 a été validé pour WB. Il convient pour détecter TRAF6 dans des échantillons de Humain et Souris.

Aperçu rapide pour TRAF6 anticorps (ABIN2666284)

Antigène: TRAF6 (TNF Receptor-Associated Factor 6 (TRAF6))

Reactivité: Humain, Souris

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TRAF6 est non-conjugé

Application: Western Blotting (WB)

Clone: T2-1SC

Détail du produit anti-TRAF6 anticorps

Purification: Affinity purified

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: phosphate-buffered solution, pH 7.2, containing 0.05 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Upon receipt, store undiluted between 2°C and 8°C.

Détails sur TRAF6

Antigène: TRAF6 (TNF Receptor-Associated Factor 6 (TRAF6))

Autre désignation: TRAF6

Sujet: The protein encoded by this gene is a member of the TNF receptor-associated factor (TRAF) protein family. TRAFs (TNF receptor-associated factors) are a family of multifunctional adaptor proteins that bind to surface receptors and recruit additional proteins to form multiprotein signaling complexes capable of promoting cellular responses. Members of the TRAF family share a common carboxy-terminal "TRAF domain" which mediates interactions with associated proteins, many also contain amino-terminal Zinc/RING finger motifs. The six known TRAFs (TRAF1-6) act as adaptor proteins for a wide range of cell surface receptors and participate in the regulation of cell survival, proliferation, differentiation, and stress responses. TRAF6 plays a critical role in innate and adaptive immunity, bone metabolism, and development of certain tissues including the nervous system. This protein has an amino terminal RING domain which is followed by four zinc-finger motifs, a central coiled-coil region and a highly conserved carboxyl terminal domain, known as the TRAF-C domain. TRAF6 deficiency results in osteopetrosis and defective IL-1, CD40, and LPS signaling as well as defects in neuronal development. Unlike other TRAF family members that mediate signaling through TNF, TRAF6 has unique binding activities that result in signaling responses from the interleukin-1 receptor (IL-1R), toll-like receptor, CD40, RANK, and p75 neurotrophin receptor. TRAF6 associates directly with CD40 and RANK, and indirectly with IL-1R/TLR through IRAK. This leads to activation of NF-κB and MAP kinase signaling pathways through downstream association with the TAB/TAK-1 complex. TRAF6 also activates Src family nonreceptor tyrosine kinases leading to Akt activation.

Pathways: Signalisation NF-kappaB, TCR Signaling, Signalisation TLR, Fc-epsilon Receptor Signaling Pathway, Neurotrophin Signaling Pathway, Activation of Innate immune Response, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Tube Formation, Hepatitis C, Toll-Like Receptors Cascades, Ubiquitin Proteasome Pathway